Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to
tackle disease-causing proteins that have historically been highly challenging to target with …

In recent years, proteolysis-targeting chimeras (PROTACs), capable of achieving targeted
protein degradation, have proven their great therapeutic potential and usefulness as …

Targeted protein degradation is a novel pharmacology established by drugs that recruit
target proteins to E3 ubiquitin ligases. Based on the structure of the degrader and the target …

Criteria for predicting the druglike properties of “beyond Rule of 5” Proteolysis Targeting
Chimeras (PROTAC) degraders are underdeveloped. PROTAC components are often …

As effective ways to regulate protein levels, targeted protein degradation technologies have
attracted great attention in recent years. Here, we established a novel integrin-facilitated …

The selective removal of misfolded, aggregated, or aberrantly overexpressed protein plays
an essential role in maintaining protein-dominated biological processes. In parallel, the …

Carbon–heteroatom bonds, most often amide and ester bonds, are the standard method to
link together two complex fragments because carboxylic acids, amines, and alcohols are …

Hijacking the cellular protein degradation system offers unique opportunities for drug
discovery, as exemplified by proteolysis-targeting chimeras. Despite their great promise for …

Targeted protein degradation (TPD), the ability to control a proteins fate by triggering its
degradation in a highly selective and effective manner, has created tremendous excitement …

Whereas the PROTAC approach to target protein degradation greatly benefits from rational
design, the discovery of small-molecule degraders relies mostly on phenotypic screening …